OnCore Login

News & Developments

Member Feature: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

April 20, 2022:

This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J, Solove Research Institute (OSUCCC) as our featured member. OSUCCC – James member Dwight Owen, MD, MSc is a medical oncologist and member of the Translational Therapeutics Program at the OSUCCC- James. Dr. Owen’s is a member of the Big Ten CRC’s correlative sciences clinical trial working group and a co-chair of the thoracic clinical trial working group. Dr. Owen shares why he is glad to be part of the Big Ten Cancer Research Consortium. Read More

Arnab Chakravarti, MD: Proton and FLASH therapy: the epitome of personalized cancer care

April 13, 2022: When I was recruited to Ohio State in 2009 as director of the Department of Radiation Oncology, one of our long-term goals was to extend our therapeutic reach by establishing central Ohio’s first proton therapy center in partnership with nearby Nationwide Children’s Hospital. The center would enable both adult and pediatric patients to receive the very latest radiotherapy – namely proton therapy – in one facility that is closer to their homes, making it a less disruptive life experience. Proton therapy uses protons, or positively charged particles found within atoms, instead of X-rays to kill cancer cells. Because it more precisely targets tumor cells, it limits radiation exposure and potential damage to surrounding tissue and organs, reducing the chance of short- and long-term side effects. This... Read More

Member Feature: University of Michigan Health Rogel Cancer Center

March 10, 2022:  This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights the University of Michigan Rogel Cancer Center as our featured member. Rogel Cancer Center member Ryan Wilcox, MD, PhD, is an associate professor of hematology/oncology at Rogel and a member of the Big Ten CRC’s lymphoid malignancies clinical trial working group. He has participated in two BTCRC trials. Dr. Wilcox shares why he’s glad to be part of the Big Ten Cancer Research Consortium. Read More

Patel and Fujioka appointed co-chairs of Big Ten CRC head and neck clinical trial working group

March 1, 2022: Manish Patel, DO and Naomi Fujioka, MD from the Masonic Cancer Center at the University of Minnesota were recently appointed as co-chairs of the Big Ten Cancer Research Consortium's Head and Neck Clinical Trial Working Group. Read More

Douglas Yee, MD: “Déjà vu all over again”

February 24, 2022: Just over 50 years ago, President Richard Nixon signed the National Cancer Act – more commonly known as the “War on Cancer.” While harnessing the resources of the federal government was an important step forward, many have commented (including current NCI director Dr. Ned Sharpless) the effort was simultaneously ambitious and naïve. Naïve in the sense that we did not yet understand our enemy. About 25 years into the “war,” the New England Journal of Medicine published an article entitled, “Cancer Undefeated” wherein declining death rates were attributed to changing incidence rates and early detection practices (Bailar, et al. N Engl J Med 336:1569 1997 PMID: 9164814), not because of advances in therapy. Read More

Member Feature: Masonic Cancer Center, University of Minnesota

February 23, 2022: This month, the Big Ten Cancer Research Consortium highlights the Masonic Cancer Center at the University of Minnesota and physician-scientist Emil Lou, MD, PhD, FACP. Investigator Spotlight: Emil Lou, MD, PhD, FACP (@cancerassassin1), Associate Professor in the Department of Medicine, Division of Hematology, Oncology and Transplantation, Department of Medicine and Graduate Faculty Program member in the Integrative Biology and Physiology Program (IBP) at the University of Minnesota; and Medical Director of the UMN Masonic Cancer Center’s Clinical Trials Office (CTO)-Solid Tumor Unit. Read More

Investigators present prostate cancer study at 2022 GU Cancers Symposium

February 18, 2022: Big Ten Cancer Research Consortium investigators presented a Trial in Progress abstract at the 2022 American Society of Clinical Oncology Genitourinary Cancer Symposium. The abstract titled, A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer, is led by David J VanderWeele, MD, PhD of the Robert H Lurie Comprehensive Cancer Center of Northwestern University. Read More

Big Ten CRC investigators present gastric, hepatocellular carcinoma studies at 2022 GI Cancers Symposium

February 14, 2022: Big Ten Cancer Research Consortium Investigators recently presented abstracts during the 2022 Gastrointestinal Cancers Symposium. The abstracts included a poster featuring the BTCRC-GI15-015 study, led by Al B. Benson III, MD of Robert H Lurie Comprehensive Cancer Center of Northwestern University, and a trials in progress poster featuring BTCRC-GI20-457 led by Kristen Renee Spencer, DO, MPH of Rutgers Cancer Institute. Read More

Big Ten CRC investigators publish results of advanced esophageal cancer study BTCRC-ESO14-012

February 12, 2022: Big Ten Cancer Research Consortium (Big Ten CRC) investigators recently published results of clinical trial BTCRC-ESO14-012 in the notable Frontiers in Oncology journal.  The publication titled, A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study, found adjuvant durvalumab in patients with residual disease in the surgical specimen following trimodality therapy (a combination of chemotherapy, radiation, and surgery) for locally advanced... Read More

Big Ten CRC BRE16-042 presented as a trial in progress at 2021 San Antonio Breast Cancer Symposium

February 11, 2022: Big Ten Cancer Research Consortium investigators presented a trial in progress abstract at the 2021 San Antonio Breast Cancer Symposium. The abstract titled, A Phase II Study of Pembrolizumab plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients, was presented by Nancy Chan, MD of Rutgers Cancer Institute of New Jersey. Read More

University of Illinois

University of Illinois

Indiana University

Indiana University

University of Iowa

University of Iowa

University of Maryland

University of Maryland

University of Michigan

University of Michigan

Michigan State

Michigan State

University of Minnesota

University of Minnesota

University of Nebraska

University of Nebraska

Northwestern University

Northwestern University

Penn State University

Penn State University

Purdue University

Purdue University

Rutgers State University

Rutgers State University

University of Wisconsin

University of Wisconsin

University of Illinois at Chicago

University of Illinois at Chicago

© 2022 All rights reserved.

Big Ten Cancer Research Consortium
7676 Interactive Way, Suite 120, Indianapolis, IN 46278

email: info@bigtencrc.org    phone: 317–921–2050